The Second European Chemokine and Cell Migration Conference 2017
About the Conference
ECMC2017 is the second European Chemokine and Cell Migration Conference. It follows the first conference, ECMC2015, chaired by Marcus Thelen, Biomedical Research Institute, Swiss Italian University, and held on 4 – 7 June, 2015, in Villars-sur-Ollon, Switzerland. For more information about the scientific programme click here.
ECMC2017 is designed to appeal to international scientists working in broad areas of research, including immunology, cell biology, structural biochemistry, inflammatory diseases and cancer. Both, academic and medical scientists will benefit from state-of-the-art talks given by world experts. A special invitation is extended to the next-generation scientists, including PhD students and postdoctoral fellows, who are encouraged to submit research abstracts for poster presentations and short talks.
We are looking forward to welcoming our friends from Europe and distant shores and all those with a keen interest in immune cell traffic in health and disease. Our newly built venue, the Royal Welsh College of Music and Drama , is ready to host the ECMC2017 and to cater to the needs of all international attendees.
Conference Chair and Organising Committee
The field of immune cell traffic control is one of the fasted growing research areas in immunology (>50,000 PubMed entries since the discovery of chemokines). Migration is the hallmark of immune cells, which ensures access of immune cells to every part of our body for the purpose of immune defence and tissue immune surveillance. Defects in immune cell traffic control frequently causes chronic inflammatory diseases and organ failure. Chemokines and other chemoattractants also contribute to tissue development and repair processes as well as secondary tumour (metastasis) formation. Consequently, much of recent PubMed entries focus on translational aspects of chemokine research, including new drugs targeting cancer metastasis, chronic infections and inflammatory diseases. Given the undisputed importance of immune cells in health and disease together with the type of signalling receptors (GPCRs) chemokines act on, it is safe to predict that novel chemokine-based therapies will emerge in the near future.